ROMosozumab early experience in female patients with severe osteoporosis in an Italian real-world setting, the ROMEO study
The rapid increase in BMD with romosozumab supports its use for reducing fracture risk in postmenopausal women with severe osteoporosis, regardless of prior bisphosphonate exposure.
Authors
- Marta Bartezaghi
- Anna Lisa Piccinelli (ORCID: https://orcid.org/0000-0001-6102-2762)
- Camilla Benini (ORCID: https://orcid.org/0000-0002-8082-5023)
- Ombretta Viapiana (ORCID: https://orcid.org/0000-0003-1917-5655)
- Francesco Pollastri (ORCID: https://orcid.org/0009-0006-1691-2196)
- Maurizio Rossini (ORCID: https://orcid.org/0000-0001-9692-2293)
- Davide Gatti (ORCID: https://orcid.org/0000-0002-7471-3076)
- Angelo Fassio (ORCID: https://orcid.org/0000-0001-9187-232X)
- Francesca Mastropaolo (ORCID: https://orcid.org/0000-0002-3225-2152)
- Rachele Fornari
- Francesco Giorgio
- Giovanni Adami (ORCID: https://orcid.org/0000-0002-8915-0755)
- Filippo Montanari
Institutions
- University of Verona (IT)
Publication Details
- Journal
- Osteoporosis International
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1007/s00198-025-07722-8
- Citations
- 2
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 3.44
Funders
- Amgen
- Università degli Studi di Verona